Verastem VSTM 深 滬
等待開盤 09-24 09:30:00 美东时间
8.18
-0.190
-2.27%
華盛通- 最 高8.40
- 今 開8.37
- 成交量 193.57万股
- 最 低 7.85
- 昨 收 8.37
- 總市值 7.41亿
- 52周最高 10.8213
- 市盈率 靜 --
- 換手率 2.14%
- 52周最低 3.43
- 委 比 -97.43%
- 總股本 9056.34万
- 歷史最高 225.84
- 量 比 0.71
- 振 幅 6.57%
- 歷史最低 2.10
- 每 手 1
- 風險率 1.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Wolfe Research Initiates Coverage On Verastem with Outperform Rating
Wolfe Research analyst Kalpit Patel initiates coverage on Verastem (NASDAQ:VSTM) with a Outperform rating.
09-17 22:05
Revolution之后， 谁能接棒KRAS新的高光？
（来源：深蓝观） 一二 | 撰文 2026年8月26日，美国FDA提前批准了Revolution Medicines的RMC-623...
09-14 18:12
美股大行评级 | Adobe绩后获多家大行齐升目标价！最高看多至270美元；甲骨文绩后现多空分歧
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从10美元升至10.5美元；摩根士丹利：维持Aurora Innovation"超配"评级，目标价从14美元升至18美元
09-14 16:05
BTIG Reiterates Buy on Verastem, Maintains $18 Price Target
BTIG analyst Jeet Mukherjee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.
09-11 18:29
Verastem Oncology To Host Investor Event On October 14 To Present Initial Efficacy And Updated Data For VS-7375 In Pancreatic, Lung, And Colorectal Cancers From Ongoing TARGET-D Clinical Development Program
Investor event and webcast to be held Wednesday, October 14, 2026, at 8:00 am ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor event on Wednesday, October 1...
09-08 19:33
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Guggenheim Maintains Buy on Verastem, Lowers Price Target to $12
Guggenheim analyst Michael Schmidt maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from $14 to $12.
08-08 00:46
Verastem shares are trading higher after the company reported better-than-expected Q2 financial results.
Verastem shares are trading higher after the company reported better-than-expected Q2 financial results.
08-07 04:56
